Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488106 | 1.00 | APAF1 (0.50) | APAF1TDP2MCL1BCL2P2RX7 | |
| Hydrochloric Acid SCHEMBL16369796 | 0.98 | APAF1 (0.48) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL11352933 | 0.96 | APAF1 (0.46) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL3465719 | 0.96 | APAF1 (0.46) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL8190848 | 0.89 | APAF1 (0.64) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL7120454 | 0.82 | S100A4 (0.41) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL27981640 | 0.82 | APAF1 (0.41) | APAF1TDP2MCL1BCL2P2RX7 | |
| SCHEMBL19230417 | 0.81 | ALDH1A1 (0.52) | APAF1TDP2MCL1BCL2CES2 | |
| SCHEMBL29364188 | 0.78 | MEN1 (0.56) | APAF1TDP2MCL1BCL2CES2 | |
| SCHEMBL354514 | 0.78 | MEN1 (0.56) | APAF1TDP2MCL1BCL2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| CN-119613555-A | Site-specific antibody conjugate and antibody-drug conjugate as specific example thereof | 阿比蒂斯有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119613317-A | Site-specific antibody conjugate and antibody-drug conjugate as specific example thereof | 阿比蒂斯有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-3943508-B1 | DUAL FUNCTION ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2024-01-10 | — | — | EP | claimed |
| CN-115397515-A | Human anti-CD 33 antibodies and uses thereof | 弗莱德哈钦森癌症中心 | 2022-11-25 | — | — | CN | claimed |
| CN-115297932-A | anti-CD 33 antibodies and uses thereof | 弗莱德哈钦森癌症中心 | 2022-11-04 | — | — | CN | claimed |
| CN-111777681-B | Antibody combined with tight junction protein-18.2 and application thereof | 康诺亚生物医药科技（成都）有限公司 | 2022-10-11 | — | — | CN | claimed |
| US-20220226339-A1 | INHIBITATION OF ACID LIPASE FOR CANCER THERAPY | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2022-07-21 | — | — | US | claimed |
| CN-114685657-A | Development and application of function-enhanced antibody blocking agent | 康诺亚生物医药科技（成都）有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114634567-A | Development and application of immunomodulator | 康诺亚生物医药科技（成都）有限公司 | 2022-06-17 | — | — | CN | claimed |
| EP-1237915-B1 | POLYNUCLEOTID ENCODING THE RG1 POLYPEPTIDE | BAYER SCHERING PHARMA AG (DE) | 2009-08-26 | — | — | EP | claimed |
| US-20080262613-A1 | Biocompatible, Biodegradable Polyurethane Materials With Controlled Hydrophobic to Hydrophilic Ratio | SYNTHES USA, LLC | 2008-10-23 | — | — | US | claimed |
| CN-100361980-C | Novel blue light material-thiotrzinone-containing anthracene derivatives | SHANGHAI INST ORGANIC CHEM (CN) | 2008-01-16 | — | — | CN | claimed |
| EP-1771490-A1 | BIOCOMPATIBLE, BIODEGRADABLE POLYURETHANE MATERIALS WITH CONTROLLED HYDROPHOBIC TO HYDROPHILIC RATIO | Synthes GmbH (CH) | 2007-04-11 | — | — | EP | claimed |
| CN-1789252-A | Novel blue light material-thiotrzinone-containing anthracene derivatives | SHANGHAI INST ORGANIC CHEM (CN) | 2006-06-21 | — | — | CN | claimed |
| WO-2006010278-A1 | BIOCOMPATIBLE, BIODEGRADABLE POLYURETHANE MATERIALS WITH CONTROLLED HYDROPHOBIC TO HYDROPHILIC RATIO | SYNTHES GMBH (CH) | 2006-02-02 | — | — | WO | claimed |
| EP-0981541-B1 | PSCA: PROSTATE STEM CELL ANTIGEN | UNIV CALIFORNIA (US) | 2004-06-02 | — | — | EP | claimed |
| EP-0699756-B1 | Mutant BR96 antibodies reactive with human carcinomas | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | claimed |
| EP-0596011-A1 | TRIFUNCTIONAL COMPOUNDS HAVING SPECIFICITY FOR MULTI-DRUG RESISTANT CELLS | HYBRITECH INCORPORATED (US) | 1994-05-11 | — | — | EP | claimed |
| WO-1993002105-A1 | TRIFUNCTIONAL COMPOUNDS HAVING SPECIFICITY FOR MULTI-DRUG RESISTANT CELLS | HYBRITECH INCORPORATED (US) | 1993-02-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226339-A1 | INHIBITATION OF ACID LIPASE FOR CANCER THERAPY | PNLIP, LPL, LIPA | APAF1 424/4885TDP2 1075/4885MCL1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.